Comprehensive Analysis of Monocyte Palmitoylation-Related Genes IFITM3 and CCL3-CCR5 Axis in Crohn’s Disease Progression: Insights from Mendelian Randomization, Multi-Omics Integration, Machine Learning, and SHAP methodology
https://www.sciencedirect.com/science/article...7126002896
"This freshly published June 4, 2026 study in Computational Biology and Chemistry provides massive, direct validation for JV Partner 2 (Immunology) by establishing an ironclad, genetically verified link between the CCL3-CCR5 axis and chronic gastrointestinal inflammation.
While the study targets Crohn's Disease (CD), it maps out an elite scientific mechanism that proves how a CCR5 blocker like leronlimab functions as an active anti-inflammatory firewall.
Here is the technical breakdown of the study’s data and its direct implications for blocking CCR5:
???? The Core Finding: The CCL3-CCR5 Pathogenic Switch
Using Mendelian Randomization (MR) and single-cell transcriptomics, researchers moved beyond general correlation to prove absolute causality between specific chemokines and Crohn's Disease progression.
The paper maps a highly destructive immune cell communication network inside inflamed tissues:
The Normal Pathway:
Resting monocytes utilize the standard CCL3-CCR1 pathway to stimulate neutrophils.
The Pathogenic Switch:
In progressing chronic inflammation, monocytes hyper-activate and establish a destructive intercellular communication loop driven specifically by the CCL3-CCR5 axis. This specific loop drives excessive immune cell recruitment, leading to persistent, un-healing tissue damage".
2. Terminating the Monocyte Inflammatory Loop
Leronlimab’s weekly 700mg dosing delivers near-100% continuous receptor occupancy, creating an absolute steric blockade on extracellular loop 2 (ECL2).
Because leronlimab completely locks the CCR5 receptor, it breaks the monocyte-centered signaling network uncovered in this study, halting the persistent infiltration driving chronic bowel wall fibrosis.
3. Bypassing the "Agnostic" Machine Learning Diagnostic Markers
The study constructed a highly accurate diagnostic model using 12 machine learning algorithms and identified a core gene signature (including IFITM3 and C2) linked to monocyte palmitoylation.
The Bypass Check: While a tumor or inflamed cell can upregulate IFITM3 internally to alter its membrane stability, the downstream consequence relies entirely on the secretion of CCL3 to bind to surface CCR5.
The Solution: By capping the surface CCR5 receptor, leronlimab effectively neutralizes the destructive potential of IFITM3 overexpression, neutralizing the pathway regardless of upstream genetic mutations."
https://www.sciencedirect.com/science/article...7126002896
"This freshly published June 4, 2026 study in Computational Biology and Chemistry provides massive, direct validation for JV Partner 2 (Immunology) by establishing an ironclad, genetically verified link between the CCL3-CCR5 axis and chronic gastrointestinal inflammation.
While the study targets Crohn's Disease (CD), it maps out an elite scientific mechanism that proves how a CCR5 blocker like leronlimab functions as an active anti-inflammatory firewall.
Here is the technical breakdown of the study’s data and its direct implications for blocking CCR5:
???? The Core Finding: The CCL3-CCR5 Pathogenic Switch
Using Mendelian Randomization (MR) and single-cell transcriptomics, researchers moved beyond general correlation to prove absolute causality between specific chemokines and Crohn's Disease progression.
The paper maps a highly destructive immune cell communication network inside inflamed tissues:
The Normal Pathway:
Resting monocytes utilize the standard CCL3-CCR1 pathway to stimulate neutrophils.
The Pathogenic Switch:
In progressing chronic inflammation, monocytes hyper-activate and establish a destructive intercellular communication loop driven specifically by the CCL3-CCR5 axis. This specific loop drives excessive immune cell recruitment, leading to persistent, un-healing tissue damage".
2. Terminating the Monocyte Inflammatory Loop
Leronlimab’s weekly 700mg dosing delivers near-100% continuous receptor occupancy, creating an absolute steric blockade on extracellular loop 2 (ECL2).
Because leronlimab completely locks the CCR5 receptor, it breaks the monocyte-centered signaling network uncovered in this study, halting the persistent infiltration driving chronic bowel wall fibrosis.
3. Bypassing the "Agnostic" Machine Learning Diagnostic Markers
The study constructed a highly accurate diagnostic model using 12 machine learning algorithms and identified a core gene signature (including IFITM3 and C2) linked to monocyte palmitoylation.
The Bypass Check: While a tumor or inflamed cell can upregulate IFITM3 internally to alter its membrane stability, the downstream consequence relies entirely on the secretion of CCL3 to bind to surface CCR5.
The Solution: By capping the surface CCR5 receptor, leronlimab effectively neutralizes the destructive potential of IFITM3 overexpression, neutralizing the pathway regardless of upstream genetic mutations."
6
